Fred, we have been down this road many times in
Post# of 9165
(Total Views: 625)
Posted On: 03/04/2017 7:16:54 PM
Fred,
we have been down this road many times in the past. Here's one from over six years ago...
Press Release Source: NanoLogix, Inc. On Monday December 13, 2010, 8:00 am EST
HUBBARD, Ohio--(BUSINESS WIRE)-- NanoLogix (PINK OTC Markets: NNLX), an innovator in the accelerated detection and identification of microorganisms, announces the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the University of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publication of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with E.Coli and Pseudomonas to follow in early 2011. For further information on the GBS trial please visit the UTHSC - Houston Newsroom at: http://www.uthouston.edu/media/newsreleases/n...id=2434326
NanoLogix Technology Focused on Domination of $150 Million U.S. Ob/Gyn GBS Testing Market
NanoLogix seeks to lead innovation in the market of GBS Ob/Gyn testing, which in the U.S. is valued at approximately $150 million annually. Initial results from UTHSC Houston last spring show the GBS Quick Tests returned reliable results in approximately four hours. With the current standard of 48-72 hours, this is a markedly significant reduction in testing time. Today’s GBS strains are resistant to ampicillin and amoxicillin and by improving standard detection speed, NanoLogix and the physicians at UTHSC Houston hope to dramatically reduce the overuse of antibiotics in pregnant women and contribute to the fight against GBS antibiotic resistance.
What I don't understand is why we NEVER actually bring rapid diagnostic products to market. Is the present regime really that clueless? Start with one item and grow the business from there. How many rapid GBS tests have we sold in the last six years?
Why not exploit the flatpack for all it is worth? License it out to anyone and everyone to get cash flow then we would have funding instead of borrowing or diluting shares.
years of excuses, excuses, excuses
Why are we always trying to hit the jackpot?
we have been down this road many times in the past. Here's one from over six years ago...
Press Release Source: NanoLogix, Inc. On Monday December 13, 2010, 8:00 am EST
HUBBARD, Ohio--(BUSINESS WIRE)-- NanoLogix (PINK OTC Markets: NNLX), an innovator in the accelerated detection and identification of microorganisms, announces the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the University of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publication of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with E.Coli and Pseudomonas to follow in early 2011. For further information on the GBS trial please visit the UTHSC - Houston Newsroom at: http://www.uthouston.edu/media/newsreleases/n...id=2434326
NanoLogix Technology Focused on Domination of $150 Million U.S. Ob/Gyn GBS Testing Market
NanoLogix seeks to lead innovation in the market of GBS Ob/Gyn testing, which in the U.S. is valued at approximately $150 million annually. Initial results from UTHSC Houston last spring show the GBS Quick Tests returned reliable results in approximately four hours. With the current standard of 48-72 hours, this is a markedly significant reduction in testing time. Today’s GBS strains are resistant to ampicillin and amoxicillin and by improving standard detection speed, NanoLogix and the physicians at UTHSC Houston hope to dramatically reduce the overuse of antibiotics in pregnant women and contribute to the fight against GBS antibiotic resistance.
What I don't understand is why we NEVER actually bring rapid diagnostic products to market. Is the present regime really that clueless? Start with one item and grow the business from there. How many rapid GBS tests have we sold in the last six years?
Why not exploit the flatpack for all it is worth? License it out to anyone and everyone to get cash flow then we would have funding instead of borrowing or diluting shares.
years of excuses, excuses, excuses
Why are we always trying to hit the jackpot?
(3)
(0)